THE APEX TIMES
Eli Lilly agrees to pay up to $3.8 billion to access AtaiBeckley’s psychedelic nasal spray
The deal would give Eli Lilly rights to a psychedelic-based, single-dose nasal spray being studied for treatment-resistant depression, as Big Pharma deepens its search for faster-acting mental health treatments.
Eli Lilly is set to pay up to $3.8 billion for access to AtaiBeckley’s psychedelic-based nasal spray, according to a report published by Yahoo Finance and re-circulated by The Daily Upside. The arrangement reflects how major drug companies are continuing to broaden beyond traditional antidepressants and toward therapies that may act on depression in different ways.
At the center of the deal is a nasal spray formulation tied to psychedelic research. The report says studies indicate it can curb treatment-resistant depression in a single dose, a potentially important distinction because treatment-resistant depression is a subtype in which many patients do not respond to standard therapies.
For Lilly, expanding a pipeline into mental health is an ongoing strategic need, and the company has repeatedly targeted areas where it believes it can translate scientific advances into meaningful clinical outcomes. A single-dose approach, if it holds up in additional data, could also change how clinics think about dosing logistics and timelines for patients who have not found relief elsewhere.
The headline number in the report is $3.8 billion, framed as the maximum amount Lilly would pay. Deals structured around milestones or conditional payments are common in pharma licensing and collaboration agreements, but the report does not provide details on the payment structure, including how much is due upfront, what triggers additional payments, or whether any commercial royalties are involved.
AtaiBeckley, the counterparty in the report, is described in this coverage in connection with the nasal spray program. However, the available information does not spell out AtaiBeckley’s broader portfolio, Lilly’s specific rights (for example, geography or indications beyond treatment-resistant depression), or whether Lilly would be responsible for late-stage development and manufacturing.
Broader interest in psychedelics has gathered momentum in recent years, especially for difficult-to-treat conditions. The attraction for established drug makers is not just the novelty of the mechanism, but the possibility of differentiated efficacy indicates and a path to address areas of unmet medical need. Still, psychedelic-adjacent development also comes with regulatory scrutiny and operational questions around clinical protocols and patient eligibility.
The report does not disclose which phase of clinical testing the nasal spray has reached, what the study size was, or the nature of the efficacy measurements used to define “curbs” treatment-resistant depression. It also does not provide safety findings, duration of response beyond the immediate effect, or data about side effects that could affect adoption in real-world settings.
What to watch next is whether Lilly and AtaiBeckley publish more granular trial results and whether regulatory filings or investor materials clarify the structure of the $3.8 billion figure. Investors and clinicians will also be looking for confirmation that the single-dose effect is durable, reproducible across patient subgroups, and supported by safety and tolerability data sufficient to advance the program.
Why It Matters
- The deal indicates renewed Big Pharma interest in psychedelic-based mental health therapies, particularly for hard-to-treat depression.
- A single-dose approach, if validated, could differentiate the program from standard antidepressant regimens that often require longer timelines.
- Milestone-heavy payments, common in pharma deals, can shift risk and reward between partners depending on clinical and regulatory outcomes.
- The lack of published trial details in the immediate reporting means the magnitude and durability of the effect remain to be independently assessed as more data emerge.
Key Facts
- Eli Lilly agreed to pay up to $3.8 billion to gain access to AtaiBeckley’s psychedelic-based nasal spray.
- The nasal spray is being studied for treatment-resistant depression.
- The report characterizes the therapy as having an effect after a single dose in studies.
- The coverage does not provide a payment breakdown or specific milestones tied to the maximum amount.
Healthcare Related
Tikr blog compares dividend outlooks for Pfizer and Kraft Heinz, arguing only one stock could fund “dividend dollars” for the next decade
A market commentary weighing dividend yields puts Kraft Heinz ahead of Pfizer on immediate yield, with Kraft Heinz at 7.2% and Pfizer at 6%, framing the comparison as a 10-year “dividend dollars” test.
Eli Lilly’s weight-loss drug draws renewed attention as an EU regulator move sets up a key Oct. 29 catalyst
A market note tied to Eli Lilly’s weight-loss pipeline points to an Oct. 29 update, after an EU drug-regulator action described as supportive of Lilly’s weight-loss pill. Investors are watching what the next milestone could mean for the program and the broader GLP-1 race.
Johnson & Johnson lifts sales outlook again, but the bigger test is how investors read its Q3 report
A fresh guidance increase outlines management confidence, yet the market reaction to Johnson & Johnson’s latest quarter may matter more than the incremental numbers themselves.
Moderna’s Phase 3 cancer vaccine win and Nasdaq-100 inclusion highlight shift toward oncology
A positive late-stage result tied to Moderna’s personalized cancer vaccine helped reframe expectations for the biotech, as the company was also added to the Nasdaq-100 index.
Eli Lilly investors who bought in 2025 focused on what the company implied, even as the stock outpaced the broader market
A Trefis-linked analysis highlighted how an investor’s $10,000 stake in Eli Lilly grew to about $15,500 from October 14, 2025 to October 15, 2026, compared with roughly $11,790 for the same sum in the S&P 500.
Bristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debate
A market analysis comparing Bristol-Myers Squibb and Johnson & Johnson in 2026 points to a valuation gap, while warning that BMY’s financial leverage and patent risks could outweigh its cheaper price. JNJ’s case rests on its diversified business model.
Moderna Shares Slip as Biotech Pullback Spurs Caution, Investors Told Not to Overreact
A market-wide retreat in biotech stocks is weighing on Moderna, but analysts cited upcoming company and partner catalysts that could help stabilize sentiment.
Pfizer set to report Q3 2026 earnings next month, with analysts bracing for profit decline
Ahead of Pfizer’s third-quarter 2026 results, market watchers are preparing for a double-digit dip in profit, underscoring how sensitive the company’s earnings outlook remains to new-product growth and shifting demand.